News Releases

2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
1
2019-04/18
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption(N Engl J Med 2019; 380:1535-1545)
2
2019-04/18
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
3
2019-04/18
How an Experimental Injection Could Revolutionize HIV Treatment
4
2019-06/11
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
5
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
6
2019-04/18
Novel antibody may suppress HIV for up to four months
7
2019-04/17
Monoclonal antibody demonstrates ‘unprecedented’ virologic suppression in HIV study
8
2019-04/17
Weekly Infusion May Be Effective, Easier HIV Therapy
9
2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
1
2019-04/18
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption(N Engl J Med 2019; 380:1535-1545)
2
2019-04/18
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
3
2019-04/18
How an Experimental Injection Could Revolutionize HIV Treatment
4
2019-06/11
United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients
5
2019-05/21
United Biopharma obtains approval from the U.S. FDA to conduct a clinical trial with UB-421 in Patients with Multi-Drug Resistance HIV-1 infection
6
2019-04/18
Novel antibody may suppress HIV for up to four months
7
2019-04/17
Monoclonal antibody demonstrates ‘unprecedented’ virologic suppression in HIV study
8
2019-04/17
Weekly Infusion May Be Effective, Easier HIV Therapy
9
President Dr. Mei-June Liao received the recognition for “Bioprocessing Executive of the year” at the 2017 Asia-Pacific Bioprocessing Excellence Forum 2017-02/24
The phase II data of UB-421 was presented at the late breaker session at CROI 2017 2017-02/15
Filed IND for UB-421 phase III clinical trial (HAART substitution) to TFDA 2017-01/15
Received certificate of occupancy for UBP’s eight-story (7000 sq Meter) headquarter building based in Huko, Hsinchu county designed for administrative, R&D and large scale protein drug manufacturing activities 2016-12/15
Filed IND for UB-921 (Anti-HER2 monoclonal antibody) phase I clinical trial to TFDA 2016-12/15
UBP entered into a licensing agreement with UBI US Holdings LLC and UBI IP Holdings, the subsidiary of United Biomedical, Inc (UBI) for exclusive US and ROW (ex-Asia) rights for development and commercialization of UB-421 2016-08/15
UB-421 for HIV treatment won the 12th National Innovation Prize given by Taiwan Biotechnology Strategic Planning Association 2015-12/15
IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD antibody, was approved by Taiwan Food and Drug Administration (TFDA) 2015-11/15
United BioPharma received approval for UB-421 Phase II clinical trial for HAART substitution treatment in treatment stabilized HIV patients from Taiwan Food and Drug Administration (TFDA) 2015-06/15
Filed an IND submission of a phase II clinical trial for HAART substitution therapy in treatment stabilized HIV patients with Taiwan Food and Drug Administration (TFDA) 2015-02/15